Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Bolus Insulin

Lilly's Lispro Authorized Generic Now Available in US Pharmacies

Here is a brief preview of this blast: Lilly announced that its insulin lispro authorized generic (LAG) is now available. In March 2019, Lilly disclosed its intention to launch the AG at a 50% lower WAC price compared to Humalog; $137.35 per vial (assumed to be a 10mL vial) and $265.20 for a package of five KwikPens. According to the press release, Lilly said it is working with payers to gain broad coverage of the LAG; however, at least one large national payer, ESI, recently said it will not cover the LAG. Below, FENIX provides thoughts and context to Lilly's LAG lispro launch.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.